LYN-1604 dihydrochloride

Research use only, not for human use.

LYN-1604 is a novel ULK1 activator.It inducing cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis.

LYN-1604 is a novel ULK1 activator.It inducing cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis.(In Vitro):LYN-1604, to be the best candidate for a ULK1 agonist. LYN-1604 induced cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis. LYN-1604 has potential for good therapeutic effects on TNBC by targeting ULK1-modulated cell death in vivo

Cell Viability Assay Cell Line:MDA-MB-231 cells Concentration:0.5, 1.0 and 2.0 μM Incubation Time:Result:Induced cell death.Autophagy ratio was increased in a dose-dependent manner.Western Blot Analysis Cell Line:MDA-MB-231 cells Concentration:0, 0.5, 1, and 2 μM Incubation Time:24 hours Result:Induced remarkable up-regulation of Beclin-1 and degradation of p62, as well as transformation of LC3-I to LC3-II.

Animal Model:24 female nude mice (BALB/c, 6-8 weeks, 20-22 g) Dosage:Low dose, 25 mg/kg; median dose, 50 mg/kg; high dose, 100 mg/kg Administration:Intragastric administration; once a day for 14 days Result:Significantly inhibited the growth of xenograft MDA-MB-231 cells. The body weights of mice were stable. By the end of the experiment, the liver and spleen weight indexes of mice were slightly increased in parts of the groups, while the kidney weight index was not affected in all dose groups.

LYN-1604 2HCl（2216753-86-3 free basel) |

Apoptosis

Apoptosis

——

——

——

2310109-38-5

657.54

C33H45Cl4N3O2

>98% (HPLC)

In Vitro:?H2O : 50 mg/mL (76.04 mM)

[H]Cl.[H]Cl.ClC1=CC=C(C(OCC2=CC=C3C=CC=CC3=C2)CN4CCN(C(CN(CC(C)C)CC(C)C)=O)CC4)C(Cl)=C1

——

(-20℃)

With Ice Pack

≥ 2 years